April 23, 2021
RFA-CA-21-023 - Proteome Characterization Centers (PCCs) for Clinical Proteomic Tumor Analysis Consortium (U24 Clinical Trial Not Allowed)
RFA-CA-21-024 - Proteogenomic Data Analysis Centers (PGDACs) for Clinical Proteomic Tumor Analysis Consortium (U24 Clinical Trial Not Allowed)
RFA-CA-21-025 - Proteogenomic Translational Research Centers (PTRCs) for Clinical Proteomic Tumor Analysis Consortium (U01 Clinical Trial Not Allowed)
National Cancer Institute (NCI)
The NCI recently announced the reissuance of the Clinical Proteomic Tumor Analysis Consortium (CPTAC). This re-issuance seeks to continue building on the current achievements in clinical cancer proteogenomics discoveries and infrastructure to accelerate molecularly oriented cancer research toward basic discovery and clinical impact.
The NCI will conduct a pre-application webinar on Monday, May 17, 2021, from 11:30 AM - 1:30 PM (ET) for the following Funding Opportunity Announcements (FOAs): Proteome Characterization Centers (PCCs), Proteogenomic Data Analysis Centers (PGDACs), and Proteogenomic Translational Research Centers (PTRCs).
NCI program staff involved in these FOAs will provide orientation to potential applicants by explaining the goals and objectives for the FOAs. The webinar will conclude with a final, open online question and answer session, with program staff available to answer questions.
Pre-registration is required to participate in the webinar, and participants may also submit their questions in advance at [email protected]. Participation in this webinar, although encouraged, is optional, and is not required for the submission of an application in response to the FOAs.
Following the webinar, the presentation will be posted on: https://proteomics.cancer.gov/funding_opportunities.
Webinar Information
The Webinar will be hosted through Webex.
Webinar Date: Monday, May 17, 11:30 AM-1:30 PM ET
Join from the meeting link:
Join by phone
Join from a video system or application
You can also dial 173.243.2.68 and enter your meeting number.